No Data
Werewolf Therapeutics Analyst Ratings
Werewolf Therapeutics Advances Innovative Cytokine Therapies
Leerink Partners Maintains Werewolf Therapeutics(HOWL.US) With Buy Rating, Maintains Target Price $13
Promising Potential of Werewolf Therapeutics' INDUKINE Platform Despite Challenges
JMP Securities Maintains Werewolf Therapeutics(HOWL.US) With Buy Rating, Maintains Target Price $12
Buy Rating for Werewolf Therapeutics: Strong Financial Position and Promising Pipeline